Cxbladder for hematuria evaluation
Cxbladder tests for hematuria evaluation are optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and help de-intensify clinical work-up in patients with a low probability Cxbladder test result. This reduces the need for referral and invasive procedures, while helping to prioritize those that require immediate care.
Effectiveness of cystoscopy. US data highlights the challenge
The need
Each year over 7 million US patients present with hematuria and 2 million are referred to urology for evaluation. 75% of these patients present with microhematuria.
The challenge
While hematuria is the most common symptom of urothelial cancer, the incidence is low among microhematuria patients and around 95% of those cystoscopies yield a negative result.
The solution
95-97% of patients presenting with microhematuria do not have urothelial cancer and 70-80% of cystoscopies can be safely avoided using a non-invasive Cxbladder test.
Genomic testing designed to optimize practice workflow
Cxbladder Triage
As a frontline diagnostic to support risk stratification, Cxbladder Triage is optimized to help de-intensify clinical work-up in microhematuria patients with a low probability Triage test result, reducing the need for referral and invasive procedures, while prioritizing those who require further investigation.
Cxbladder Triage is included in the AUA Microhematuria Guideline, the first and only UBTM recommended with supporting Level A Evidence.*
Cxbladder Detect
Cxbladder Detect is designed to improve practice workflow and efficiency in urological care, while giving patients the best experience possible. The test is optimized for the risk stratification of patients presenting with microhematuria and helps to de-intensify clinical work-up in in those with a low probability Detect test result.
Featured news
Cxbladder Triage incorporated into AUA Microhematuria Guideline
The American Urological Association (AUA) has included Cxbladder Triage in an amendment to its clinical guideline for the management of patients presenting with microhematuria.
Start your Cxbladder journey
Contact our customer service team
Learn more about the Cxbladder suite and how to implement it in your practice.
Cxbladder Triage
A test optimized to risk stratify and rule out urothelial cancer as a frontline diagnostic
Analyzes gene expression alongside information on known UC risk factors like age, gender and smoking history to help rule out microhematuria patients with a low risk of disease, while prioritizing those who require further investigation.
Included in AUA/ SUFU MH Guideline* (the first and only recommended UBTM with supporting Level A Evidence) as an alternative to cystoscopy for risk stratification and the evaluation of appropriately counseled intermediate risk patients. Safely de-intensifies clinical workup in patients with a low probability Triage test result, while prioritizing those that require immediate care.
Supports a new model for clinical practice and resource utilization. This deployment model provides care to the greatest number of patients and offers clinically actionable information at the earliest point in the patient care pathway.
Featured resources
Platform Reduces Unnecessary Cystoscopies for Hematuria
Dr. Zachary Klaassen interviews Dr. John Sfakianos about implementing the Cxbladder platform for microhematuria risk stratification and bladder cancer surveillance. Dr. Sfakianos discusses how high-quality biomarkers address the longstanding need to avoid over-diagnosing patients with microhematuria, where historically everyone received cystoscopy despite most having no significant findings.
Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines
Dr. Jay Raman and Dr. Yair Lotan sit down with Dr. Zachary Klaassen to discuss the latest developments in microhematuria evaluation. Topics include the unmet need in risk stratifying patients, the evolution of the AUA Microhematuria Guideline from 2020 to 2025, and the role of urinary biomarkers in optimizing patient care, including Cxbladder Triage, a test now included in the Guideline*.
SESAUA 2025 Symposium: Cxbladder Triage - Risk Stratification for Patients with Microhematuria
Dr. Zachary Klaassen covers the recent inclusion of Cxbladder Triage in an amendment to the AUA Microhematuria Guideline*, and the benefits Cxbladder Triage offered in reducing the burden of unnecessary cystoscopies for those with a lower risk of cancer, resulting in less patient discomfort and morbidity.
Cxbladder Detect
A test for the risk stratification of urothelial cancer
Enables reliable risk stratification. Safely de-intensifies clinical workup in patients with a low probability Detect test result, while prioritizing those that require immediate care.
Spares patients with a low probability Detect test result the discomfort, anxiety and risks of an invasive procedure.
A reliable adjunct when other tests and procedures are inconclusive. Resolves atypical cytology and equivocal cystoscopy.
Optimize your clinical practice while improving the patient experience
The Cxbladder suite helps you prioritize your time and clinical resources on those that need it the most, streamlining practice workflow and increasing overall efficiency.
Cxbladder works for both you and the patient. Spare patients with a low probability of urothelial cancer the discomfort, anxiety and risks of an invasive procedure. With urine-based sampling and the option of in-home sample collection, the Cxbladder suite allows you to optimize your clinical practice while delivering the best patient experience possible.
Cxbladder is a precision test that delivers exceptional performance and clinically actionable results
Cxbladder is an objective test with high sensitivity and NPV.
The Cxbladder suite is supported by an evidence portfolio that includes over 25 peer reviewed publications in leading medical journals.
Cxbladder Triage is now included in the American Urological Association (AUA) Microhematuria Guideline, the first and only UBTM recommended with supporting Level A Evidence.
The Cxbladder suite of tests have been used by over 5,000 urologists in more than 100,000 patients.
How Cxbladder works
The sampling process
Cxbladder's non-invasive urine sampling system is easy for patients to use, streamlining deployment in-clinic.
The science
Cxbladder is an objective test with high sensitivity and NPV that delivers exceptional performance and clinically actionable results. The test works at a molecular level, analyzing biomarker genes to help risk stratify urothelial cancer.
The test report
The Cxbladder test report have been developed in consultation with leading urologists and provides the patient’s Cxbladder score, alongside an interpretation of the results and an assay description.
Start your Cxbladder journey
Contact our customer service team
Learn more about the Cxbladder suite and how to implement it in your practice.
Adopting Cxbladder in your clinic
Implementing Cxbladder
Our team are ready to guide and support you in the deployment and use of Cxbladder. Learn more implementation.
Start your Cxbladder journey
Contact our customer service team to learn more about the Cxbladder suite and how to implement it in your practice.
Cxbladder is available around the world
Cxbladder is available in the United States, and in countries across Asia and South America. Cxbladder is also available in New Zealand, Australia, and Israel.
References
* Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004490.